{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:14Z","timestamp":1791475334240,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021981","name":"Roche Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejca.2026.116936","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:18:30Z","timestamp":1783628310000},"page":"116936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression"],"prefix":"10.1016","volume":"245","author":[{"given":"Rashmi","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2991-5575","authenticated-orcid":false,"given":"Gopal P.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1683-3902","authenticated-orcid":false,"given":"Mathieu","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2278-9950","authenticated-orcid":false,"given":"Tanya","family":"Gillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-4081","authenticated-orcid":false,"given":"Zhaolin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116936_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.ejca.2026.116936_bib2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/cancers17081340","article-title":"Identification of driver mutations and risk stratification in lung adenocarcinoma via liquid biopsy","volume":"17","author":"Pathak","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116936_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236580","article-title":"Molecular profiling of non-small cell lung cancer","volume":"15","author":"Forsythe","year":"2020","journal-title":"PLOS One"},{"key":"10.1016\/j.ejca.2026.116936_bib4","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.3390\/cancers17213500","article-title":"Advances in precision oncology: from molecular profiling to regulatory-approved targeted therapies","volume":"17","author":"Brlek","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116936_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154943","article-title":"Targeting mutations in cancer","volume":"132","author":"Waarts","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2026.116936_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic THerapy for Locally Advanced and Metastatic Non\u2013small Cell Lung Cancer: A Review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116936_bib7","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ejca.2026.116936_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116936_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of egfr tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116936_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: a double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116936_bib13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116936_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2026.116936_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115622","article-title":"TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma","volume":"227","author":"Gallina","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116936_bib16","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib18","article-title":"Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries","volume":"38","author":"de","year":"2024","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.ejca.2026.116936_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-014-0140-3","article-title":"Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?","volume":"12","author":"Tripathy","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2026.116936_bib20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/PO.19.00338","article-title":"Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice","author":"de Moor","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70262","article-title":"Temporal effect on pd-l1 detection and novel insights into its clinical implications in non\u2013small cell lung cancer","volume":"13","author":"Pathak","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116936_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1186\/s12864-016-3195-z","article-title":"Visualizing tumor evolution with the fishplot package for R","volume":"17","author":"Miller","year":"2016","journal-title":"BMC Genom"},{"key":"10.1016\/j.ejca.2026.116936_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.ejca.2026.116936_bib26","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLOS Med"},{"key":"10.1016\/j.ejca.2026.116936_bib27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"Treatment outcome of atypical EGFR mutations in the German national network genomic medicine lung cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib28","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/bjc.2014.210","article-title":"Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts","volume":"110","author":"Li","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116936_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41698-024-00726-3","article-title":"Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway","volume":"8","author":"Li","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib30","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116936_bib31","doi-asserted-by":"crossref","first-page":"45237","DOI":"10.18632\/oncotarget.9931","article-title":"Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma","volume":"7","author":"Belchis","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116936_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC \u2014 mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib33","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116936_bib34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116936_bib35","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.annonc.2022.01.004","article-title":"Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients","volume":"33","author":"Chen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116936_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103935","article-title":"Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"9","author":"Li","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116936_bib37","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108389","article-title":"Cancer evolution: Darwin and beyond","volume":"40","author":"Vendramin","year":"2021","journal-title":"EMBO J"},{"key":"10.1016\/j.ejca.2026.116936_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251080","article-title":"Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR","volume":"16","author":"Alwithenani","year":"2021","journal-title":"PLOS One"},{"key":"10.1016\/j.ejca.2026.116936_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13059-024-03302-x","article-title":"Immune evasion impacts the landscape of driver genes during cancer evolution","volume":"25","author":"Gourmet","year":"2024","journal-title":"Genome Biol"},{"key":"10.1016\/j.ejca.2026.116936_bib40","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:23:20Z","timestamp":1787415800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0959804926007173"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116936","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116936"}}